212 related articles for article (PubMed ID: 29947754)
1. Primary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients.
Biton Y; Rosero S; Moss AJ; Goldenberg I; Kutyifa V; McNitt S; Polonsky B; Baman JR; Zareba W
Europace; 2019 Feb; 21(2):339-346. PubMed ID: 29947754
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients With Long QT Syndrome.
Wang M; Peterson DR; Rosero S; McNitt S; Rich DQ; Seplaki CL; Polonsky B; Goldenberg I; Zareba W
J Am Coll Cardiol; 2021 Nov; 78(21):2076-2088. PubMed ID: 34794689
[TBL] [Abstract][Full Text] [Related]
3. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
Olde Nordkamp LR; Wilde AA; Tijssen JG; Knops RE; van Dessel PF; de Groot JR
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):91-100. PubMed ID: 23275262
[TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter defibrillator treatment in long QT syndrome patients: a national study on adherence to international guidelines.
Sundström E; Jensen SM; Diamant UB; Rydberg A
Scand Cardiovasc J; 2017 Apr; 51(2):88-94. PubMed ID: 27936942
[TBL] [Abstract][Full Text] [Related]
5. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
[TBL] [Abstract][Full Text] [Related]
6. Left cardiac sympathetic denervation for the management of life-threatening ventricular tachyarrhythmias in young patients with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome.
Schneider HE; Steinmetz M; Krause U; Kriebel T; Ruschewski W; Paul T
Clin Res Cardiol; 2013 Jan; 102(1):33-42. PubMed ID: 22821214
[TBL] [Abstract][Full Text] [Related]
7. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management.
Goldenberg I; Bradley J; Moss A; McNitt S; Polonsky S; Robinson JL; Andrews M; Zareba W;
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):893-901. PubMed ID: 20233272
[TBL] [Abstract][Full Text] [Related]
8. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry.
Providência R; Marijon E; Lambiase PD; Bouzeman A; Defaye P; Klug D; Amet D; Perier MC; Gras D; Algalarrondo V; Deharo JC; Leclercq C; Fauchier L; Babuty D; Bordachar P; Sadoul N; Piot O; Boveda S
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873687
[TBL] [Abstract][Full Text] [Related]
9. Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy.
DeWitt ES; Triedman JK; Cecchin F; Mah DY; Abrams DJ; Walsh EP; Gauvreau K; Alexander ME
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1057-63. PubMed ID: 25262116
[TBL] [Abstract][Full Text] [Related]
10. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Philbert BT; Torp-Pedersen C; Riahi S; Jøns C
Europace; 2018 Sep; 20(FI2):f217-f224. PubMed ID: 29684191
[TBL] [Abstract][Full Text] [Related]
11. Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up.
Mönnig G; Köbe J; Löher A; Eckardt L; Wedekind H; Scheld HH; Haverkamp W; Milberg P; Breithardt G; Schulze-Bahr E; Böcker D
Heart Rhythm; 2005 May; 2(5):497-504. PubMed ID: 15840474
[TBL] [Abstract][Full Text] [Related]
12. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
[TBL] [Abstract][Full Text] [Related]
13. Risk of death in the long QT syndrome when a sibling has died.
Kaufman ES; McNitt S; Moss AJ; Zareba W; Robinson JL; Hall WJ; Ackerman MJ; Benhorin J; Locati ET; Napolitano C; Priori SG; Schwartz PJ; Towbin JA; Vincent GM; Zhang L
Heart Rhythm; 2008 Jun; 5(6):831-6. PubMed ID: 18534367
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study.
Christensen AM; Bjerre J; Schou M; Jons C; Vinther M; Gislason GH; Johansen JB; Nielsen JC; Petersen HH; Riahi S; Ruwald AC
Europace; 2019 Mar; 21(3):465-474. PubMed ID: 30535192
[TBL] [Abstract][Full Text] [Related]
15. Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable-Prévention Primaire registry.
Defaye P; Boveda S; Klug D; Beganton F; Piot O; Narayanan K; Périer MC; Gras D; Fauchier L; Bordachar P; Algalarrondo V; Babuty D; Deharo JC; Leclercq C; Marijon E; Sadoul N;
Europace; 2017 Sep; 19(9):1478-1484. PubMed ID: 28340096
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
[TBL] [Abstract][Full Text] [Related]
17. Contemporary rates and outcomes of single- vs. dual-coil implantable cardioverter defibrillator lead implantation: data from the Israeli ICD Registry.
Leshem E; Suleiman M; Laish-Farkash A; Konstantino Y; Glikson M; Barsheshet A; Goldenberg I; Michowitz Y;
Europace; 2017 Sep; 19(9):1485-1492. PubMed ID: 27702848
[TBL] [Abstract][Full Text] [Related]
18. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
[TBL] [Abstract][Full Text] [Related]
19. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.
Greenlee RT; Go AS; Peterson PN; Cassidy-Bushrow AE; Gaber C; Garcia-Montilla R; Glenn KA; Gupta N; Gurwitz JH; Hammill SC; Hayes JJ; Kadish A; Magid DJ; McManus DD; Multerer D; Powers JD; Reifler LM; Reynolds K; Schuger C; Sharma PP; Smith DH; Suits M; Sung SH; Varosy PD; Vidaillet HJ; Masoudi FA
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29581222
[TBL] [Abstract][Full Text] [Related]
20. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
